Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.

ABSTRACT: Low-grade gliomas (LGGs) are slow-growing tumors in the central nervous system (CNS). Patients characteristically show the onset of seizures or neurological deficits due to the predominant LGG location in high-functional brain areas. As a molecular hallmark, LGGs display mutations in the isocitrate dehydrogenase (IDH) enzymes, resulting in an altered cellular energy metabolism and the production of the oncometabolite D-2-hydroxyglutarate. Despite the remarkable progress in improving the extent of resection and adjuvant radiotherapy and chemotherapy, LGG remains incurable, and secondary malignant transformation is often observed. Therefore, novel therapeutic approaches are urgently needed. In recent years, immunotherapeutic strategies have led to tremendous success in various cancer types,

SUBMITTER: Gallus M 

PROVIDER: S-EPMC10378701 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature